^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report
Published date:
01/29/2021
Excerpt:
...the patient was diagnosed with late-stage lung adenocarcinoma with MET exon14 skipping gene mutation….Crizotinib was administered (250 mg bid) for 8 months, and her disease achieved partial regression (PR) and progression-free survival (PFS), which lasted for 8 months. The patient also reached PR after the second-line treatment with cabozantinib, and is currently under follow-up, with an overall survival (OS) of >12 months.
DOI:
10.1097/MD.0000000000024300
